Renalytix PLC

Renalytix has 437,018,680 basic shares outstanding, with no dilution from potential share issuance, as the diluted share count is equal to the basic count. The company's market price is $1.80, resulting in a market capitalization of $786.6 million. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and return metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. This limits the ability to assess performance relative to the cohort median or industry benchmarks. Renalytix's revenue concentration and geographic exposure are not disclosed in the available data. The company does not provide segment-level revenue breakdowns or geographic revenue distribution in the input data, making it difficult to evaluate diversification or exposure to specific markets. Growth trajectory is not quantified in the input data, as no outlook numeric deltas or revenue history are provided. The absence of forward-looking guidance or historical performance data limits the ability to assess the company's growth potential. The company is flagged for liquidity risk, as no balance-sheet inputs are available and no going-concern language is present in source documents. Dilution risk is assessed as low, with no evidence of potential share issuance or capital-raising activities in the data provided. No recent events, such as filings or transcripts, are included in the input data to inform the company's current strategic or operational developments.